Try one of the below options to narrow down your search.
 |
Documents may be browsed by date, eg; Today, May, 2013.
Past years can be browsed too, eg; 2012, 2011, 2010, 2009 ...
Documents can be searched within a period by browsing to the date and then using the search form; or by direct links, eg; Media releases from 2013
Document tags (shown below the document date, eg; Schedule, SAForms, consultation ...) have highest priority when search results are ranked, followed by title, abstract and full text of document.
Parentheses and the keywords and, or and not have special meaning in search terms. And is implicit and can be omitted; or must be specified.
Remember to group or statements with parentheses if they are beside and statements.
Search examples
- consultation
- Search for consultations
- media and not antibiotics
- Search for media related documents that don't mention antibiotics.
- (media or consultation) and vaccines
- Search for media releases and consultation documents mentioning vaccinations.
Search term: PTAC
PHARMAC web pages that matched your search: (hide)
Application Tracker – “PTAC minutes, subcommittee minutes, consultation letters, and notifications that have been released relating to that”
PHARMAC documents that matched your search:
Annual Review 2012
(36 pages, 2535 KB)
2013/01/31
“PTAC, the Consumer Advisory Committee and the PHARMAC Board • Improving PHARMAC’s consideration of Māori”
Pharmaceutical Management Agency Annual Review 2012 2011/12 Highlights Pharmaceutical funding • Community and cancer pharmaceutical funding managed on budget - $777.4 million • 24 new investments in medicine – including 14 new medicines and 10 widened access • New investments…
2012-06 Reproductive and Sexual Health Subcommittee Minutes
(7 pages, 47 KB)
2013/01/22
“PTAC) and PTAC Subcommittees 2008. Note that this document is not necessarily a complete record”
Reproductive and Sexual Health Subcommittee of PTAC Meeting held 25 June 2012 (minutes for web publishing) Reproductive and Sexual Health Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and…
Proposal to list sugammadex (Bridion) for reversal of neuromuscular blockade; Closing Date: Friday 15 February 2013; Contact: Geraldine MacGibbon
(2 pages, 116 KB)
2013/01/30
“PTAC) at its April 2012 meeting. In summary, the Subcommittee recommended that sugammadex be funded”
30 January 2013 Proposal to list sugammadex (Bridion) for reversal of neuromuscular blockade PHARMAC is seeking feedback on a proposal to list sugammadex (Bridion) in Section H of the Pharmaceutical Schedule (the national Preferred Medicines List (PML)), subject to the…
Request for Proposals - Supply of fentanyl transdermal patches
(11 pages, 209 KB)
2013/01/28
“PTAC or its relevant Subcommittee or any other relevant clinical expert sought by PHARMAC; any other”
28 January 2013 Dear Supplier REQUEST FOR PROPOSALS – SUPPLY OF FENTANYL TRANSDERMAL PATCHES PHARMAC invites proposals for the supply of fentanyl transdermal patches in New Zealand. This request for proposals (RFP) letter incorporates the following schedules: …
Approval of funding of sildenafil for Raynaud's phenomenon and bosentan for children with pulmonary arterial hypertension; Contact: Notifications; Posted: 2013-01-28
(2 pages, 115 KB)
2013/01/28
“PTAC) considered the trial data in December 2012 and recommended that an endothelin receptor antagonist”
28 January 2013 Approval of funding of sildenafil for Raynaud’s phenomenon and bosentan for children with pulmonary arterial hypertension PHARMAC is pleased to announce the approval of proposals for funding sildenafil for Raynaud’s phenomenon from 1 March 2013 and bosentan…
January 2013 organisational chart
(1 page, 41 KB)
2013/01/23
“PTAC Secretary/ Panel Co-ordinator Accounts Co-ordinator HR Manager HR Advisor x2 HR Administrator/Payroll”
Organisational Chart January 2013 Chief Executive Manager, Schedule & Contracts Manager, Analysis & Assessment Manager, Corporate & External Relations Manager, Access & Optimal Use (AOU) & Māori Health Operations Team Assistant Director Operations Medical Director Senior Schedule Analyst Manager Technology…
Proposal to fund unapproved pharmaceutical treatments for various conditions; Closing Date: 5pm, Friday 1 February 2013; Contact: Geraldine MacGibbon
(10 pages, 188 KB)
2013/01/14
“PTAC reviewed PTAC’s minutes and the Special Authority criteria suggested by PTAC for benzbromarone”
14 January 2013 Proposal to fund unapproved pharmaceutical treatments for various conditions PHARMAC and Link Pharmaceuticals Limited have entered into a provisional agreement for the funding and supply of 11 pharmaceuticals that do not have Medsafe consent (i.e. are not…
Economic Assessment Guide Explained
(11 pages, 240 KB)
2012/12/14
“PTAC - the Pharmacology and Therapeutics Advisory Committee - and also clinical advisors on its specialist subcommittees”
Pharmaceutical Management Agency Cost-Utility Analysis (CUA) Explained Cost-Utility Analysis (CUA) at PHARMAC Questions and Answers go to page 8 >> The process described in this document is intended to be indicative of the process that PHARMAC may use when undertaking…
Decision to amend the diphtheria, pertussis and tetanus vaccine (Boostrix) listing; Contact: Notifications; Posted: 2012-12-12
(3 pages, 108 KB)
2012/12/12
“PTAC). This will be notified to treating clinicians and published on PHARMAC’s website. For the avoidance”
12 December 2012 Decision to amend the diphtheria, pertussis and tetanus vaccine (Boostrix) listing PHARMAC is pleased to announce the approval of a proposal to amend the criteria for accessing funding for the combination diphtheria, pertussis and tetanus vaccine (under…
Proposal to fund sildenafil for the treatment of Raynaud's phenomenon; Closing Date: Closed; Contact: Stephen Woodruffe
(2 pages, 113 KB)
2012/12/10
“PTAC) recommended that sildenafil should also be funded for patients with secondary Raynaud’s phenomenon”
10 December 2012 Proposal to fund sildenafil for the treatment of Raynaud’s phenomenon PHARMAC is seeking feedback on a proposal to: Fund sildenafil for patients with Raynaud’s phenomenon who meet the Special Authority eligibility criteria. The proposal does not…
Page updated on 20 May 2013
